Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint reduction (LIFE) substudy

JAMA

Volumn 288, Issue 12, 2002, Pages 1491-1498

  Kjeldsen, Sverre E ^a   Dahlöf, Björn ^b   Devereux, Richard B ^a   Julius, Stevo ^c   Aurup, Peter ^d   Edelman, Jonathan ^e   Beevers, Gareth ^f   De Faire, Ulf ^g   Fyhrquist, Frej ^h   Ibsen, Hans ⁱ   Kristianson, Krister ^j   Lederballe Pedersen, Ole ^k   Lindholm, Lars H ^l   Nieminen, Markku S ^m   Omvik, Per ⁿ   Oparil, Suzanne ^o   Snapinn, Steven ^p   Wedel, Hans ^j  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f CITY HOSPITAL   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h Karolinska University Hospital ^*  (Finland)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^k Merck Research Laboratories Scandinavia   (Sweden)

^l VIBORG HOSPITAL   (Denmark)

^m UMEÅ UNIVERSITY   (Sweden)

ⁿ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^o University of Alabama at Birmingham   (United States)

^p NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC HYPERTENSION;

EID: 0037174372     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.12.1491     Document Type: Article

References (37)

1. For the The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study. Rational, design and methods
2. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: Results of prospectively designed overviews of randomised trials
3. High risk of cerebro-cardiovascular morbidity in well-treated male hypertensives
4. Mortality in patients of the Glasgow Blood Pressure Clinic
5. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: Results from the Primary Prevention Trial in Göteborg, Sweden
6. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
7. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
8. Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analysis of 109 treatment studies
9. Angiotensin II receptor antagonists: An emerging new class of cardiovascular therapeutics
10. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
11. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
12. Randomised trial in intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1
13. Systolic vs diastolic blood pressure and risk of coronary heart disease: The Framingham Study
14. Systolic blood pressure, arterial rigidity and risk of stroke: The Framingham Study
15. Prevention of stroke by antihypertensive drug treatment in older subjects with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
16. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
17. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
18. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
19. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
20. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE Study
21. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE Study
22. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products
23. Electrocardiographic identification of left ventricular hypertrophy: Test performance in relation to definition of hypertrophy and presence of obesity
24. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer electrocardiogram interpretation: Necropsy validation
25. Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: Results of a correlated data base approach
26. Improved electrocardiographic diagnosis of left ventricular hypertrophy
27. An updated coronary risk profile: A statement for health professionals
28. Estimating causal effects from large data sets using propensity scores
29. Stroke is more common than myocardial infarction in hypertension: Analysis based on 11 major randomised intervention trials
30. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension
31. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials
32. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
33. Regression of left ventricular hypertrophy as a surrogate endpoint for morbid events in hypertension treatment trials
34. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease
35. Are betablockers efficacious as first-line therapy for hypertension in the elderly? A systematic review